🔎 Trials Near Me

Utama › Limfadenopati Imunoblastik › New York

Kajian klinikal Limfadenopati Imunoblastik di New York

5 kajian untuk Limfadenopati Imunoblastik sedang mencari peserta di lokasi di New York.

Bandar di New York

Teks kajian rasmi (Bahasa Inggeris)

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • dan 5 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04803201

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  • Icahn School of Medicine at Mount Sinai, New York
  • Memorial Sloan Kettering Cancer Center, New York
  • Weill Cornell Medicine, New York
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06561048

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

  • Clinical Trial Site, New York
  • Clinical Trial Site, New York
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT06393738

A Registry for People With T-cell Lymphoma

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack
  • Memorial Sloan Kettering Westchester (All protocol activities), Harrison
  • Weill Cornell Medical Center (Data Collection Only), New York
  • dan 2 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 20 Mei 2026 · NCT05978141

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

  • Columbia University, New York
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2025 · NCT04234048

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.